|
A rare case of de novo CD5+ diffuse large B-cell lymphoma in leukemic phase and positive for CD13
Giovanni Carulli, Eugenio Mario Ciancia, Francesco Caracciolo, Paola Sammuri, Cristiana Domenichini, Maria Immacolata Ferreri, Alessia Di Vita, Virginia Ottaviano, Martina Rousseau, Mario Petrini
|
|
- Eugenio Mario Ciancia
Second Division of Pathology, AOUP, Pisa, Italy
- Francesco Caracciolo
Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy
- Paola Sammuri
Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy
- Cristiana Domenichini
Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy
- Maria Immacolata Ferreri
Laboratory of Medical Genetics, AOUP, Pisa, Italy
- Alessia Di Vita
Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy
- Virginia Ottaviano
Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy
- Martina Rousseau
Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy
- Mario Petrini
Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy
|
Abstract
We report a case of de novo diffuse large B-cell lymphoma (DLBCL) in leukemic phase, positive for both CD5 and CD13. Morphologic evaluation, flow cytometric immunophenotyping, karyotyping and polymerase chain reaction studies were performed. Neoplastic lymphocytes appeared as blast-like cells, positive for CD19, CD20, CD5, CD13, CD79a, HLADR, and with restriction for surface immunoglobulin K light chains. Rearrangement of IgH gene, BCL2/IgH translocation and complex karyotype were found. The patient was treated with RCOMP regimen and achieved complete remission. However, only one month after the first restaging of disease, the patient presented with symptoms attributable to central nervous system involvement and her clinical conditions worsened rapidly. While both CD5 expression and leukemic presentation are uncommon findings in DLBCL, positivity for CD13 is very rare. The outcome of our patient shows the poor prognosis of CD5+ DLBCL with leukemic presentation. The possible role of CD13 coexpression is discussed.
Keywords
CD5, CD13, diffuse large B-cell lymphoma, DLBCL, flow cytometry
|
|
|